NeuroPace director granted 913 shares at $13

Geiger Uri reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Geiger Uri reported acquisition or exercise transactions in this Form 4 filing.

NeuroPace Inc director Uri Geiger received 913 shares of Common Stock as a grant on March 20, 2026 at $13.00 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. Following the grant, he holds 14,858 shares directly and an additional 4,432,948 shares indirectly through Accelmed Partners II LP, where he has sole voting and dispositive power over the held shares.

Insider Trade Summary

Grant/Award: 913 shares

Grant/Award 2 txns

Insider Geiger Uri

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	913	$13.00	$12K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 14,858 shares (Direct); Common Stock — 4,432,948 shares (Indirect, See footnote)

Footnotes (2)

F1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
F2. Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NPCE director Uri Geiger report?

Director Uri Geiger reported receiving 913 NeuroPace (NPCE) Common Stock shares as a grant at $13.00 per share. The award was issued under the non-employee director compensation policy instead of cash quarterly retainer fees, making it a stock-based form of director compensation.

Was the NPCE insider transaction a market purchase or a compensation grant?

The NPCE insider transaction was a compensation grant, not a market purchase. Uri Geiger received 913 shares of Common Stock under the non-employee director compensation policy in lieu of quarterly cash retainer fees, reflecting routine equity-based board compensation rather than an open-market buy.

How many NPCE shares does Uri Geiger hold directly and indirectly after this filing?

After this filing, Uri Geiger holds 14,858 NeuroPace shares directly. He also has indirect ownership of 4,432,948 shares held by Accelmed Partners II LP, over which he has sole voting and dispositive power through his role as managing partner of Accelmed Partners II, LLC.

Who holds the large indirect NeuroPace (NPCE) position linked to Uri Geiger?

The large indirect NeuroPace position is held by Accelmed Partners II LP. Accelmed Partners II, LLC is its general partner, and Uri Geiger, as managing partner of that LLC, has sole voting and dispositive power over 4,432,948 NPCE shares owned by Accelmed Partners II LP.

What is the significance of the indirect NPCE holdings reported in this Form 4?

The Form 4 shows 4,432,948 NPCE shares held indirectly by Accelmed Partners II LP, with Uri Geiger controlling voting and dispositive power. This indicates a substantial stake associated with an investment entity he manages, alongside his smaller direct holding of 14,858 shares after the recent grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/24/2026 - 04:47 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Geiger Uri

(Last)

(First)

(Middle)

C/O NEUROPACE, INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW

CALIFORNIA

94043

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/20/2026		A		913⁽¹⁾	A	$13	14,858	D
Common Stock								4,432,948	I	See footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

2. Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR